We are live on ! Find out more
SA

Sicart Associates Portfolio holdings

AUM $408M
1-Year Est. Return 38.15%
This Fund
S&P 500
This Quarter Est. Return
+15.96%
1 Year Est. Return
+38.15%
3 Year Est. Return
+99.11%
5 Year Est. Return
+126.46%
10 Year Est. Return
AUM
$237M
AUM Growth
+$30M
Cap. Flow
+$2.19M
Cap. Flow %
0.93%
Top 10 Hldgs %
52.99%
Holding
82
New
2
Increased
8
Reduced
24
Closed
4

Top Buys

Rank Stock Value
1
NXPI icon
NXP Semiconductors
NXPI
+$4.99M
2
KHC icon
Kraft Heinz
KHC
+$4.71M
3
T icon
AT&T
T
+$561K
4
OSUR icon
OraSure Technologies
OSUR
+$311K
5
ROK icon
Rockwell Automation
ROK
+$204K

Sector Composition

Rank Sector Weight
1 Healthcare 22.23%
2 Miscellaneous 16.9%
3 Energy 16.74%
4 Technology 13.33%
5 Consumer Staples 9.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BGC icon
76
BGC Group
BGC
$5.77B
$226K 0.1%
42,650
ROK icon
77
Rockwell Automation
ROK
$46.3B
$211K 0.09%
+1,200
New +$204K
MUFG icon
78
Mitsubishi UFJ Financial
MUFG
$267B
$74K 0.03%
15,000
BA icon
79
Boeing
BA
$166B
-1,940
Closed -$626K
META icon
80
Meta Platforms (Facebook)
META
$1.71T
-3,120
Closed -$409K
NMRK icon
81
Newmark Group
NMRK
$2.58B
-10,399
Closed -$83K
VEA icon
82
Vanguard FTSE Developed Markets ETF
VEA
$234B
-5,887
Closed -$218K

Similar funds

Sicart Associates's Q1 2019 Portfolio in Review

As of Q1 2019, Sicart Associates held 82 positions worth $237M, up 15% from $207M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sicart Associates's Q1 2019 filing shows 2 new, 8 increased, 24 reduced and 4 closed positions. Its largest new stake was NXP Semiconductors: 56,750 shares worth $5.03M. The largest sale was Ionis Pharmaceuticals, an estimated $6.77M.

By sector, the portfolio is most concentrated in Healthcare at 22% of assets, down from 22% a quarter earlier, followed by Miscellaneous and Energy.

  • Sicart Associates's largest Q1 2019 buy was NXP Semiconductors: 56,750 shares worth $5.03M.
  • Sicart Associates added most to Kraft Heinz in Q1 2019, an estimated $4.71M increase.
  • Sicart Associates's biggest Q1 2019 reduction was Ionis Pharmaceuticals, cutting an estimated $6.77M.
  • Sicart Associates fully exited Boeing in Q1 2019, selling an estimated $626K.
  • Sicart Associates's ten largest holdings make up 53% of its $237M portfolio in Q1 2019.
  • Sicart Associates opened 2 new positions and closed 4 in Q1 2019.
  • Sicart Associates's portfolio value rose 15% quarter-over-quarter to $237M.

Based on Sicart Associates's 13F filing for Q1 2019, filed 1 May 2019.